Author: Sonire Therapeutics

Sonire Therapeutics Awarded $13 Million Through NEDO Deep-Tech Startups Support Program (DTSU) to Advance Global Commercialization of Pancreatic Cancer Treatment

June 17, 2026
Sonire Therapeutics Completes Enrollment in SUNRISE-I Randomized Controlled Trial of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer

June 1, 2026

Sonire Therapeutics Awarded $13 Million Through NEDO Deep-Tech Startups Support Program (DTSU) to Advance Global Commercialization of Pancreatic Cancer Treatment